Ten weeks to live: A population-based study on treatment and survival of patients with metastatic pancreatic cancer in the south of the Netherlands

Acta Oncologica

Volumn 54, Issue 3, 2015, Pages 403-410

  Bernards, Nienke ^a,b   Mohammad, Nadia Haj ^c   Creemers, Geert Jan ^b   De Hingh, Ignace H J T ^b   Van Laarhoven, Hanneke W M ^c   Lemmens, Valery E P P ^a,d  

^a The Netherlands   (Netherlands)

^b CATHARINA HOSPITAL   (Netherlands)

^c ACADEMIC MEDICAL CENTER   (Netherlands)

^d ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER MORTALITY; CANCER PALLIATIVE THERAPY; CANCER SURVIVAL; COMORBIDITY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; METASTATIC PANCREATIC CANCER; NETHERLANDS; OVERALL SURVIVAL; PANCREAS CANCER; PRESCRIPTION; PRIORITY JOURNAL; RISK FACTOR; SOCIAL STATUS; SURVIVAL RATE; SURVIVAL TIME; ADENOCARCINOMA; AGE FACTORS; AGED, 80 AND OVER; EPIDEMIOLOGY; HUMANS; LIVER NEOPLASMS; MIDDLE AGED; MORTALITY; PALLIATIVE CARE; PANCREATIC NEOPLASMS; PATHOLOGY; PERITONEAL CAVITY; PERITONEAL NEOPLASMS; REGISTRIES; REGRESSION ANALYSIS; SECONDARY; SOCIOECONOMIC FACTORS; TIME FACTORS;

ANTINEOPLASTIC AGENTS;

ADENOCARCINOMA; ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; FEMALE; HUMANS; LIVER NEOPLASMS; MALE; MIDDLE AGED; NETHERLANDS; PALLIATIVE CARE; PANCREATIC NEOPLASMS; PERITONEAL CAVITY; PERITONEAL NEOPLASMS; REGISTRIES; REGRESSION ANALYSIS; SOCIOECONOMIC FACTORS; TIME FACTORS;

EID: 84924236290     PISSN: 0284186X     EISSN: 1651226X     Source Type: Journal    
DOI: 10.3109/0284186X.2014.953257     Document Type: Article

References (25)

1. Moller H, Linklater KM, Robinson D. A visual summary of the EUROCARE-4 results: A UK perspective. Br J Cancer 2009;101(Suppl 2):S110-4.
2. Lemmens VE, Bosscha K, van der Schelling G, Brenninkmeijer S, Coebergh JW, de Hingh IH. Improving outcome for patients with pancreatic cancer through centralization. Br J Surg 2011;98:1455-62.
3. Seufferlein T, Bachet JB, Van Cutsem E, Rougier P. Pancreatic adenocarcinoma: ESMO-ESDO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2012;23(Suppl 7):vii33-40.
4. Pancreatic cancer in the UK. Lancet 2011;378:1050.
5. Worni M, Guller U, White RR, Castleberry AW, Pietrobon R, Cerny T, et al. Modest improvement in overall survival for patients with metastatic pancreatic cancer: A trend analysis using the surveillance, epidemiology, and end results registry from 1988 to 2008. Pancreas 2013;42:1157-63.
6. Baxter NN, Whitson BA, Tuttle TM. Trends in the treatment and outcome of pancreatic cancer in the United States. Ann Surg Oncol 2007;14:1320-6.
7. Sharp L, Carsin AE, Cronin-Fenton DP, O'Driscoll D, Comber H. Is there under-treatment of pancreatic cancer? Evidence from a population-based study in Ireland. Eur J Cancer 2009;45:1450-9.
8. De Angelis R, Francisci S, Baili P, Marchesi F, Roazzi P, Belot A, et al. The EUROCARE-4 database on cancer survival in Europe: Data standardisation, quality control and methods of statistical analysis. Eur J Cancer 2009;45:909-30.
9. Bjerregaard JK, Mortensen MB, Schonnemann KR, Pfeiffer P. Characteristics, therapy and outcome in an unselected and prospectively registered cohort of pancreatic cancer patients. Eur J Cancer 2013;49:98-105.
10. Boyd CA, Benarroch-Gampel J, Sheffield KM, Cooksley CD, Riall TS. 415 patients with adenosquamous carcinoma of the pancreas: A population-based analysis of prognosis and survival. J Surg Res 2012;174:12-9.
11. Cress RD, Yin D, Clarke L, Bold R, Holly EA. Survival among patients with adenocarcinoma of the pancreas: A population-based study (United States). Cancer Causes Control 2006;17:403-9.
12. Burris HA, 3rd, Moore MJ, Andersen J, Green MR, Rothenberg ML, Modiano MR, et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: A randomized trial. J Clin Oncol 1997;15:2403-13.
13. Moore MJ, Goldstein D, Hamm J, Figer A, Hecht JR, Gallinger S, et al. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: A phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 2007;25:1960-6.
14. Neoptolemos JP, Dunn JA, Stocken DD, Almond J, Link K, Beger H, et al. Adjuvant chemoradiotherapy and chemotherapy in resectable pancreatic cancer: A randomised controlled trial. Lancet 2001;358:1576-85.
15. Oettle H, Post S, Neuhaus P, Gellert K, Langrehr J, Ridwelski K, et al. Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: A randomized controlled trial. JAMA 2007;297:267-77.
16. Bernards N, Creemers GJ, Nieuwenhuijzen GA, Bosscha K, Pruijt JF, Lemmens VE. No improvement in median survival for patients with metastatic gastric cancer despite increased use of chemotherapy. Ann Oncol 2013;24:3056-60.
17. Krzyzanowska MK, Weeks JC, Earle CC. Treatment of locally advanced pancreatic cancer in the real world: Population-based practices and effectiveness. J Clin Oncol 2003;21:3409-14.
18. Cheung MC, Yang R, Byrne MM, Solorzano CC, Nakeeb A, Koniaris LG. Are patients of low socioeconomic status receiving suboptimal management for pancreatic adenocarcinoma? Cancer 2010;116:723-33.
19. National Working Group on Gastrointestinal Cancers. Guideline: Pancreatic cancer. The Netharlands: Comprehensive Cancer Centre; 2011.
20. Schildmann J, Tan J, Salloch S, Vollmann J. 'Well, I think there is great variation.': a qualitative study of oncologists' experiences and views regarding medical criteria and other factors relevant to treatment decisions in advanced cancer. Oncologist 2013;18:90-6.
21. Sultana A, Smith CT, Cunningham D, Starling N, Neoptolemos JP, Ghaneh P. Meta-analyses of chemotherapy for locally advanced and metastatic pancreatic cancer. J Clin Oncol 2007;25:2607-15.
22. Conroy T, Desseigne F, Ychou M, Bouche O, Guimbaud R, Becouarn Y, et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. New Engl J Med 2011;364:1817-25.
23. Ko AH. FOLFIRINOX: A small step or a great leap forward? J Clin Oncol 2011:29:3727-9.
24. Von Hoff DD, Ervin T, Arena FP, Chiorean EG, Infante J, Moore M, et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. New Engl J Med 2013;369:1691-703.
25. de Wilde RF, Besselink MG, van der Tweel I, de Hingh IH, van Eijck CH, Dejong CH, et al. Impact of nationwide centralization of pancreaticoduodenectomy on hospital mortality. Br J Surg 2011;99:404-10.